Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiling Lu

Showing results (201-210 of 224) with videos related to

Pageof 23
Sort By:
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Journal of Hepatology|April 28, 2016
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancerBeatrice Bissig-Choisat, Claudia Kettlun-Leyton, Xavier D Legras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature|August 10, 2018
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 responseGang Chen, Alexander C Huang, Wei Zhang, et al.
Nature Communications|July 9, 2022
Multi-modal molecular programs regulate melanoma cell stateMiles C Andrews, Junna Oba, Chang-Jiun Wu, et al.
Nature|December 12, 2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Science Advances|February 9, 2022
A functional genomic approach to actionable gene fusions for precision oncologyJun Li, Hengyu Lu, Patrick Kwok-Shing Ng, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
The Journal of Clinical Investigation|April 5, 2016
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsGao Zhang, Dennie T Frederick, Lawrence Wu, et al.
Pageof 23

Showing results (201-210 of 224) with videos related to

Sort By:
Pageof 23
Cancer Discovery|September 14, 2017
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling RolesVito W Rebecca, Michael C Nicastri, Noel McLaughlin, et al.
Journal of Hepatology|April 28, 2016
Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancerBeatrice Bissig-Choisat, Claudia Kettlun-Leyton, Xavier D Legras, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
A Modified Nucleoside 6-Thio-2'-Deoxyguanosine Exhibits Antitumor Activity in GliomasShengnan Yu, Shiyou Wei, Milan Savani, et al.
Nature|August 10, 2018
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 responseGang Chen, Alexander C Huang, Wei Zhang, et al.
Nature Communications|July 9, 2022
Multi-modal molecular programs regulate melanoma cell stateMiles C Andrews, Junna Oba, Chang-Jiun Wu, et al.
Nature|December 12, 2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Nature|September 28, 2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomasHezhe Lu, Shujing Liu, Gao Zhang, et al.
Science Advances|February 9, 2022
A functional genomic approach to actionable gene fusions for precision oncologyJun Li, Hengyu Lu, Patrick Kwok-Shing Ng, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
The Journal of Clinical Investigation|April 5, 2016
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitorsGao Zhang, Dennie T Frederick, Lawrence Wu, et al.
Pageof 23